GillesSallesMD

Hematologic Oncology

Physician

Overview of Dr. Salles

Dr. Gilles Salles is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Université Claude Bernard Lyon and has been in practice 32 years. He is one of 495 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(314) 266-7918

Education & Training

Université Claude Bernard LyonClass of 1989

Certifications & Licensure

NY State Medical License 2021 - 2025

Clinical Trials

A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma Start of enrollment: 2021 May 04
Active, not recruiting
Phase 2
Roles: Contact
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders Start of enrollment: 2000 Jul 01
Recruiting
Roles: Contact
A Study of Mosunetuzumab in People With Follicular Lymphoma Start of enrollment: 2022 May 27
Recruiting
Phase 2
Roles: Contact
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma Start of enrollment: 2019 May 29
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Start of enrollment: 2023 Mar 14
Recruiting
Phase 2
Roles: Contact
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma Start of enrollment: 2024 Jan 08
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

575 citations
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
Elias Campo, Elaine S Jaffe, James R Cook, Leticia Quintanilla-Martinez, Steven H Swerdlow
Blood. 2022-09-15
11 citations
CAR T-cell therapy in large B cell lymphoma.
Alexander P Boardman, Gilles Salles
Hematological Oncology. 2023-06-01
29 citations
Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma.
Ana Alarcon Tomas, Joshua A Fein, Shalev Fried, Jessica R Flynn, Sean M Devlin
Leukemia. 2023-01-01

Press Mentions

DLBCL: Polatuzumab Vedotin Enhances Progression-Free SurvivalDecember 17th, 2021
DLBCL: PFS but No OS Benefit with Polatuzumab-Vedotin Add-OnDecember 17th, 2021
$Incyte : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCL$
Incyte : MorphoSys and Incyte Announce Three-Year Results from Phase 2 L-MIND Study of Tafasitamab in Combination with Lenalidomide for the Treatment of Relapsed or Refractory DLBCLJune 9th, 2021
Join now to see all